Molecular Pathology of Inflammatory Bowel Disease-Associated Neoplasia

  • Takeshi Uehara
  • Deqin Ma
  • Antonia R. SepulvedaEmail author
Part of the Molecular Pathology Library book series (MPLB, volume 7)


Patients with inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) have a greater risk of developing colorectal cancer (CRC) as compared to patients without colitis, requiring increased surveillance colonoscopy. Chronic colitis may progress to dysplasia and in turn dysplastic lesions carry a high risk of progression to adenocarcinoma.

Although many molecular players are common with sporadic colorectal carcinogenesis, since IBD-associated dysplasia and cancers are initiated in a specific inflammatory milieu, these lesions are significantly different at the molecular level. This chapter will review the most recent advances in molecular alterations observed in IBD-associated neoplastic lesions. Importantly, in view of these differences, approaches used for early detection and specific targeted therapies may differ between IBD-associated and sporadic forms of CRC and pre-cancer lesions.


Inflammatory Bowel Disease Ulcerative Colitis KRAS Mutation Inflammatory Bowel Disease Patient BRAF Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2003;18(Suppl 2):1–5.PubMedCrossRefGoogle Scholar
  2. 2.
    Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin Diagn Pathol. 1996;13:339–57.PubMedGoogle Scholar
  3. 3.
    Itzkowitz SH, Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology. 2004;126:1634–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. quiz 524.PubMedCrossRefGoogle Scholar
  6. 6.
    Boland CR, Luciani MG, Gasche C, Goel A. Infection, inflammation, and gastrointestinal cancer. Gut. 2005;54:1321–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Karrasch T, Jobin C. NF-kappaB and the intestine: friend or foe? Inflamm Bowel Dis. 2008;14:114–24.PubMedCrossRefGoogle Scholar
  8. 8.
    Rose-John S, Scheller J, Elson G, Jones SA. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol. 2006;80:227–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Chalaris A, Garbers C, Rabe B, Rose-John S, Scheller J. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol. 2011;90:484–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501.PubMedCrossRefGoogle Scholar
  11. 11.
    Stenson WF. Prostaglandins and epithelial response to injury. Curr Opin Gastroenterol. 2007;23:107–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:553–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Maia L, Dinis J, Cravo M, et al. Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway? Cancer Genet Cytogenet. 2005;162:68–73.PubMedCrossRefGoogle Scholar
  14. 14.
    Willenbucher RF, Aust DE, Chang CG, et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol. 1999;154:1825–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Bronner MP, O’Sullivan JN, Rabinovitch PS, et al. Genomic biomarkers to improve ulcerative colitis neoplasia surveillance. Am J Pathol. 2008;173:1853–60.PubMedCrossRefGoogle Scholar
  16. 16.
    Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002;94:1421–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Redston MS, Papadopoulos N, Caldas C, Kinzler KW, Kern SE. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology. 1995;108:383–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Tomlinson I, Ilyas M, Johnson V, et al. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer. J Pathol. 1998;184:148–52.PubMedCrossRefGoogle Scholar
  19. 19.
    Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res. 1992;52: 741–5.PubMedGoogle Scholar
  20. 20.
    Lynch HT, Lynch JF. Hereditary cancer: family history, diagnosis, molecular genetics, ecogenetics, and management strategies. Biochimie. 2002;84:3–17.PubMedCrossRefGoogle Scholar
  21. 21.
    Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology. 1992;103:1602–10.PubMedGoogle Scholar
  22. 22.
    Yin J, Harpaz N, Tong Y, et al. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1993; 104:1633–9.PubMedGoogle Scholar
  23. 23.
    Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107:369–78.PubMedGoogle Scholar
  24. 24.
    Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000;60:3333–7.PubMedGoogle Scholar
  25. 25.
    Yagishita H, Yoshida T, Ishiguro K, Numata Y, Okayasu I. Epithelial and stromal genetic instability linked to tumor suppressor genes in ulcerative colitis-associated tumorigenesis. Scand J Gastroenterol. 2008;43:559–66.PubMedCrossRefGoogle Scholar
  26. 26.
    Holzmann K, Klump B, Borchard F, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer. 1998;76:1–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Meek DW. The p53 response to DNA damage. DNA Repair (Amst). 2004;3:1049–56.CrossRefGoogle Scholar
  28. 28.
    Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994;331:213–21.PubMedCrossRefGoogle Scholar
  29. 29.
    van Dieren JM, Wink JC, Vissers KJ, et al. Chromosomal and microsatellite instability of adenocarcinomas and dysplastic lesions (DALM) in ulcerative colitis. Diagn Mol Pathol. 2006;15:216–22.PubMedCrossRefGoogle Scholar
  30. 30.
    van der Woude CJ, Moshage H, Homan M, Kleibeuker JH, Jansen PL, van Dekken H. Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis. J Clin Pathol. 2005;58:811–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Chen R, Bronner MP, Crispin DA, Rabinovitch PS, Brentnall TA. Characterization of genomic instability in ulcerative colitis neoplasia leads to discovery of putative tumor suppressor regions. Cancer Genet Cytogenet. 2005;162:99–106.PubMedCrossRefGoogle Scholar
  32. 32.
    Takahashi T, Shigematsu H, Shivapurkar N, et al. Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer. 2005;118:924–31.CrossRefGoogle Scholar
  33. 33.
    Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000;60:4864–8.PubMedGoogle Scholar
  34. 34.
    Schulmann K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology. 2005;129:74–85.PubMedCrossRefGoogle Scholar
  35. 35.
    Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 1998;58:3942–5.PubMedGoogle Scholar
  36. 36.
    Mikami T, Yoshida T, Numata Y, et al. Low frequency of promoter methylation of O6-methylguanine DNA methyltransferase and hMLH1 in ulcerative colitis-associated tumors: comparison with sporadic colonic tumors. Am J Clin Pathol. 2007;127:366–73.PubMedCrossRefGoogle Scholar
  37. 37.
    Konishi K, Shen L, Wang S, Meltzer SJ, Harpaz N, Issa JP. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007;132:1254–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Chang DK, Goel A, Ricciardiello L, et al. Effect of H(2)O(2) on cell cycle and survival in DNA mismatch repair-deficient and -proficient cell lines. Cancer Lett. 2003;195:243–51.PubMedCrossRefGoogle Scholar
  39. 39.
    Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA. 2003;100:143–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Kim J, Leung W, Wu L, Graham D, Sepulveda A. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells: a link with gastric carcinogenesis. Gastroenterology. 2000;118:A867.CrossRefGoogle Scholar
  41. 41.
    Park DI, Park SH, Kim SH, et al. Effect of Helicobacter pylori infection on the expression of DNA mismatch repair protein. Helicobacter. 2005;10:179–84.PubMedCrossRefGoogle Scholar
  42. 42.
    Sepulveda AR, Yao Y, Yan W, et al. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology. 2010; 138:1836–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Souza RF, Lei J, Yin J, et al. A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasms [see comments]. Gastroenterology. 1997;112:40–5.PubMedCrossRefGoogle Scholar
  44. 44.
    Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573–7.PubMedGoogle Scholar
  45. 45.
    Sato F, Shibata D, Harpaz N, et al. Aberrant methylation of the HPP1 gene in ulcerative colitis-associated colorectal carcinoma. Cancer Res. 2002;62:6820–2.PubMedGoogle Scholar
  46. 46.
    Azarschab P, Porschen R, Gregor M, Blin N, Holzmann K. Epigenetic control of the E-cadherin gene (CDH1) by CpG methylation in colectomy samples of patients with ulcerative colitis. Genes Chromosomes Cancer. 2002;35:121–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Matsumura S, Oue N, Ito R, et al. The promoter methylation status of the DNA repair gene O6-methylguanine-DNA methyltransferase in ulcerative colitis. Virchows Arch. 2003;443:518–23.PubMedCrossRefGoogle Scholar
  48. 48.
    Petko Z, Ghiassi M, Shuber A, et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11:1203–9.PubMedGoogle Scholar
  49. 49.
    Dhir M, Montgomery EA, Glockner SC, et al. Epigenetic regulation of WNT signaling pathway genes in inflammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg. 2008;12:1745–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Lin Z, Hegarty JP, Cappel JA, et al. Identification of disease-associated DNA methylation in intestinal tissues from patients with inflammatory bowel disease. Clin Genet. 2011;80:59–67.PubMedCrossRefGoogle Scholar
  51. 51.
    Gloria L, Cravo M, Pinto A, et al. DNA hypomethylation and proliferative activity are increased in the rectal mucosa of patients with long-standing ulcerative colitis. Cancer. 1996;78:2300–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Sepulveda AR, Jones D, Ogino S, et al. CpG methylation analysis–current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn. 2009;11:266–78.PubMedCrossRefGoogle Scholar
  53. 53.
    Aust DE, Haase M, Dobryden L, et al. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int J Cancer. 2005;115:673–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Benhattar J, Saraga E. Molecular genetics of dysplasia in ulcerative colitis. Eur J Cancer. 1995;31A:1171–3.PubMedCrossRefGoogle Scholar
  55. 55.
    Wu F, Zhang S, Dassopoulos T, et al. Identification of microRNAs associated with ileal and colonic Crohn’s disease. Inflamm Bowel Dis. 2010;16:1729–38.PubMedCrossRefGoogle Scholar
  56. 56.
    Dalal SR, Kwon JH. The role of MicroRNA in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2010;6:714–22.Google Scholar
  57. 57.
    Olaru AV, Selaru FM, Mori Y. et al. Dynamic changes in the expression of MicroRNA-31 during inflammatory bowel disease-associated neoplastic transformation. Inflamm Bowel Dis. 2011;17:221–31.PubMedCrossRefGoogle Scholar
  58. 58.
    Garrity-Park MM, Loftus EV Jr, Sandborn WJ, Bryant SC, Smyrk TC. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol. 2010;105:1610–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Takeshi Uehara
    • 1
  • Deqin Ma
    • 2
  • Antonia R. Sepulveda
    • 3
    Email author
  1. 1.Department of Laboratory MedicineShinshu University School of MedicineMatsumotoJapan
  2. 2.Department of PathologyUniversity of Iowa Hospitals and ClinicsIowa CityUSA
  3. 3.Department of Pathology & Cell BiologyColumbia UniversityNew YorkUSA

Personalised recommendations